Anaptysbio annual stock-based compensation
2015
2016
2017
2021
2022
2023
2024
2025
Anaptysbio Stock-Based Compensation Growth & History (ANAB)
Anaptysbio's stock-based compensation was $36.1M for fiscal 2025.
View full Anaptysbio company overviewAnaptysbio annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $36.1M | $2.0M | +5.94% |
| 2024 | 2024-12-31 | $34.0M | $843,000 | +2.54% |
| 2023 | 2023-12-31 | $33.2M | $5.8M | +21.38% |
| 2022 | 2022-12-31 | $27.4M | $12.0M | +78.25% |
| 2021 | 2021-12-31 | $15.3M | — | — |
| 2017 | 2017-12-31 | $4.4M | $3.2M | +277.41% |
| 2016 | 2016-12-31 | $1.2M | $556,000 | +92.05% |
| 2015 | 2015-12-31 | $604,000 | — | — |
Anaptysbio quarterly stock-based compensation
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $14.2M | $5.0M | +55.05% |
| Q4 2025 | 2025-12-31 | $8.5M | $322,000 | +3.93% |
| Q3 2025 | 2025-09-30 | $9.2M | $968,000 | +11.82% |
| Q2 2025 | 2025-06-30 | $9.2M | $1.7M | +22.47% |
| Q1 2025 | 2025-03-31 | $9.2M | −$961,000 | −9.49% |
| Q4 2024 | 2024-12-31 | $8.2M | $73,000 | +0.90% |
| Q3 2024 | 2024-09-30 | $8.2M | $382,000 | +4.89% |
| Q2 2024 | 2024-06-30 | $7.5M | −$883,000 | −10.48% |
| Q1 2024 | 2024-03-31 | $10.1M | $1.3M | +14.35% |
| Q4 2023 | 2023-12-31 | $8.1M | $1.4M | +21.33% |
| Q3 2023 | 2023-09-30 | $7.8M | $1.5M | +24.49% |
| Q2 2023 | 2023-06-30 | $8.4M | $1.8M | +26.57% |
| Q1 2023 | 2023-03-31 | $8.9M | $1.1M | +14.44% |
| Q4 2022 | 2022-12-31 | $6.7M | $2.7M | +68.05% |
| Q3 2022 | 2022-09-30 | $6.3M | $1.9M | +43.70% |
| Q2 2022 | 2022-06-30 | $6.7M | $3.0M | +80.43% |
| Q1 2022 | 2022-03-31 | $7.7M | $4.4M | +133.54% |
| Q4 2021 | 2021-12-31 | $4.0M | — | — |
| Q3 2021 | 2021-09-30 | $4.4M | — | — |
| Q2 2021 | 2021-06-30 | $3.7M | — | — |
| Q1 2021 | 2021-03-31 | $3.3M | — | — |
Anaptysbio stock-based compensation trends
Between the periods ended 2015-12-31 and 2025-12-31, Anaptysbio's stock-based compensation increased from $604,000 to $36.1M, a change of $35.5M. The latest reported quarter, Q1 2026, shows $14.2M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Anaptysbio source filings ↗